OSTEOSARCOMA, Pediatric Clinics of North America, vol.44, issue.4, pp.973-89, 1997. ,
DOI : 10.1016/S0031-3955(05)70540-X
Osteosarcoma (osteogenic sarcoma), Orphanet Journal of Rare Diseases, vol.2, issue.1, p.6, 2007. ,
DOI : 10.1186/1750-1172-2-6
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols, Journal of Clinical Oncology, vol.20, issue.3, pp.776-90, 2002. ,
DOI : 10.1200/JCO.2002.20.3.776
The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity, New England Journal of Medicine, vol.314, issue.25, pp.1600-1606, 1986. ,
DOI : 10.1056/NEJM198606193142502
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience., Journal of Clinical Oncology, vol.10, issue.1, pp.5-15, 1992. ,
DOI : 10.1200/JCO.1992.10.1.5
Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A pediatric oncology group study, Medical and Pediatric Oncology, vol.84, issue.2, pp.87-92, 1995. ,
DOI : 10.1002/mpo.2950240205
Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A pediatric oncology group phase II study, Cancer, vol.9, issue.5, pp.1898-903, 1993. ,
DOI : 10.1002/1097-0142(19930301)71:5<1898::AID-CNCR2820710529>3.0.CO;2-Q
Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults., Journal of Clinical Oncology, vol.5, issue.8, pp.1191-1199, 1987. ,
DOI : 10.1200/JCO.1987.5.8.1191
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, Journal of Clinical Oncology, vol.23, issue.9, pp.2004-2015, 2005. ,
DOI : 10.1200/JCO.2005.06.031
Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma, Future Oncology, vol.2, issue.3, pp.333-376, 2006. ,
DOI : 10.2217/14796694.2.3.333
Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy, Cancer, vol.5, issue.11, pp.2447-56, 2003. ,
DOI : 10.1002/cncr.11799
Adjuvant and neoadjuvant chemotherapy in osteosarcoma, Chir Organi Mov, vol.86, pp.253-68, 2001. ,
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma, Expert Review of Anticancer Therapy, vol.9, issue.8, pp.1035-1084, 2009. ,
DOI : 10.1586/era.09.69
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival???A Report From the Children's Oncology Group, Journal of Clinical Oncology, vol.26, issue.4, pp.633-641, 2008. ,
DOI : 10.1200/JCO.2008.14.0095
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Review of Anticancer Therapy, vol.8, issue.2, pp.151-160, 2008. ,
DOI : 10.1586/14737140.8.2.151
Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma), Expert Opinion on Investigational Drugs, vol.5, issue.11, pp.1703-1718, 2008. ,
DOI : 10.1083/jcb.124.4.619
Novel agents in development for pediatric sarcomas, Current Opinion in Oncology, vol.21, issue.4, pp.332-339, 2009. ,
DOI : 10.1097/CCO.0b013e32832c94e2
Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma, Current Cancer Drug Targets, vol.6, issue.2, pp.123-156, 2006. ,
DOI : 10.2174/156800906776056473
Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes, International Journal of Immunopharmacology, vol.9, issue.2, pp.141-50, 1987. ,
DOI : 10.1016/0192-0561(87)90088-9
Delivery of macrophage-augmenting factors encapsulated in liposomes for destruction of tumor metastases, Prog Clin Biol Res, vol.102, pp.347-55, 1982. ,
Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide, Cancer Res, vol.43, pp.2010-2014, 1983. ,
Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages, Cancer Res, vol.45, pp.14-22, 1985. ,
Activation of cytolytic activity in peripheral blood, International Journal of Cancer, vol.43, issue.3, pp.380-385, 1993. ,
DOI : 10.1002/ijc.2910550307
Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes, J Pharmacol Exp Ther, vol.268, pp.1032-1041, 1994. ,
Enhancement of Canine Pulmonary Alveolar Macrophage Cytotoxic Activity Against Canine Osteosarcoma Cells, Cancer Biotherapy & Radiopharmaceuticals, vol.14, issue.2, pp.121-129, 1999. ,
DOI : 10.1089/cbr.1999.14.121
Comparative studies of cytotoxicity and the release of TNF-alpha, nitric oxide, and eicosanoids of liver macrophages treated with lipopolysaccharide and liposome-encapsulated MTP-PE, J Immunol, vol.155, pp.2595-604, 1995. ,
Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor, Clin Cancer Res, vol.5, pp.4249-58, 1999. ,
Liposomal muramyl tripeptide upregulates 20 adhesion molecules on the surface of human monocytes, Oncol Res, vol.7, pp.253-260, 1995. ,
Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice, J Immunol, vol.135, pp.1372-1379, 1985. ,
Carrier-based strategies for targeting protein and peptide drugs to the lungs, The AAPS Journal, vol.7, issue.1 ,
DOI : 10.1208/aapsj070104
Liposomal, Nanoparticle, and Conjugated Formulations of Anticancer Agents, Clinical Cancer Research, vol.11, issue.23 ,
DOI : 10.1158/1078-0432.CCR-05-1895
Comparative Pharmacokinetics of Free Muramyl Tripeptide Phosphatidyl Ethanolamine (MTP-PE) and Liposomal MTP-PE, Journal of Pharmaceutical Sciences, vol.82, issue.10, pp.997-1001, 1993. ,
DOI : 10.1002/jps.2600821005
Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients., Journal of Clinical Oncology, vol.7, issue.12, pp.1915-1940, 1989. ,
DOI : 10.1200/JCO.1989.7.12.1915
Prostaglandin E2 Affects Differently the Release of Inflammatory Mediators from Resident Macrophages by LPS and Muramyl Tripeptides, Mediators of Inflammation, vol.8, issue.6 ,
DOI : 10.1080/09629359990306
Therapy for Osteosarcoma in Dogs With Intravenous Injection of Liposome-Encapsulated Muramyl Tripeptide, JNCI Journal of the National Cancer Institute, vol.81, issue.12, pp.935-943, 1989. ,
DOI : 10.1093/jnci/81.12.935
Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma., Journal of Clinical Oncology, vol.9, issue.2, pp.259-67, 1991. ,
DOI : 10.1200/JCO.1991.9.2.259
Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously, J Biol Response Mod, vol.4, pp.298-309, 1985. ,
Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma, Cancer Res, vol.46, pp.994-1002, 1986. ,
Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients, Cancer Immunology Immunotherapy, vol.35, issue.6, pp.357-62, 1990. ,
DOI : 10.1007/BF01786885
Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice, J Interferon Cytokine Res, vol.15, pp.585-92, 1995. ,
Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma, Invasion Metastasis, vol.9, pp.75-88, 1989. ,
In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide, Am J Physiol, vol.270, pp.429-463, 1996. ,
Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages, Cancer Immunology, Immunotherapy, vol.55, issue.5, pp.285-92, 1991. ,
DOI : 10.1007/BF01756592
Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes, International Journal of Cancer, vol.4, issue.4, pp.495-500, 1986. ,
DOI : 10.1002/ijc.2910380407
Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine, Cancer Res, vol.49, pp.4665-70, 1989. ,
Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration., Journal of Clinical Oncology, vol.10, issue.8, pp.1310-1316, 1992. ,
DOI : 10.1200/JCO.1992.10.8.1310
Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE, J Immunol, vol.135, pp.1477-83, 1985. ,
The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide, Cancer Immunology Immunotherapy, vol.18, issue.2 ,
DOI : 10.1007/BF00205745
Cytostatic Activity of Canine Plastic-Adherent Mononuclear Cells Against Canine Osteosarcoma Cells, Cancer Biotherapy, vol.8, issue.2, pp.137-181, 1993. ,
DOI : 10.1089/cbr.1993.8.137
Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremit??ten, Klinische P??diatrie, vol.211, issue.04, pp.260-70, 1999. ,
DOI : 10.1055/s-2007-1019701
Combination Therapy with Ifosfamide and Liposome-Encapsulated Muramyl Tripeptide, Journal of Immunotherapy, vol.17, issue.2, pp.181-93, 1995. ,
DOI : 10.1097/00002371-199504000-00007
Sequential therapy with chemotherapeutic drugs and liposome-encapsulated muramyl tripeptide: determination of potential interactions between these agents, Oncol Res, vol.4, pp.413-421, 1992. ,
Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group., Journal of Clinical Oncology, vol.15, issue.1, pp.76-84, 1997. ,
DOI : 10.1200/JCO.1997.15.1.76
Complexities in Interpretation of Osteosarcoma Clinical Trial Results, Journal of Clinical Oncology, vol.26, issue.18, pp.3103-3107, 2008. ,
DOI : 10.1200/JCO.2008.17.3484
Osteosarcoma: The Same Old Drugs or More?, Journal of Clinical Oncology, vol.26, issue.18, pp.3102-3105, 2008. ,
DOI : 10.1200/JCO.2008.17.1108
Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial, Journal of Clinical Oncology, vol.20, issue.2, pp.426-459, 2002. ,
DOI : 10.1200/JCO.2002.20.2.426
Treatment of osteosarcoma at first recurrence after contemporary therapy, Cancer, vol.61, issue.10, pp.2214-2235, 2005. ,
DOI : 10.1002/cncr.21417
Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells, Clinical Cancer Research, vol.10, issue.23, pp.8114-8123, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0353
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine, Cancer Res, vol.50, pp.2979-86, 1990. ,
Initial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancer, J Biol Response Mod, vol.9, pp.492-500, 1990. ,
Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma, American Journal of Clinical Oncology, vol.18, issue.2, pp.93-102, 1995. ,
DOI : 10.1097/00000421-199504000-00001
Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): Can ibuprofen reduce fever and chills without compromising immune stimulation?, Cancer Immunology Immunotherapy, vol.83, issue.1, pp.45-51, 1993. ,
DOI : 10.1007/BF01789130
Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities, Neoplasma, vol.50, pp.176-84, 2003. ,
Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid), Cancer Immunology Immunotherapy, vol.66, issue.A, pp.211-231, 1992. ,
DOI : 10.1007/BF01741788